Si-Bone (NASDAQ:SIBN) specializes in innovative medical devices focusing on the surgical treatment of musculoskeletal disorders, particularly those affecting the SI (sacroiliac) joint in the pelvis. The company's flagship product, the iFuse Implant System, represents a pioneering approach to minimally invasive surgery designed to alleviate pain and improve quality of life for patients suffering from SI joint dysfunction. Si-Bone is committed to advancing healthcare by developing and delivering effective solutions that address unmet needs within orthopedic and spine surgery markets. Its objective revolves around enhancing patient outcomes and providing value to the healthcare system through clinical leadership, education, and ongoing research and development projects aimed at expanding its portfolio and improving surgical techniques.